Literature DB >> 23347466

Current options for management of biliary atresia.

Amy Gallo1, Carlos O Esquivel.   

Abstract

It is encouraging that we are improving the technical aspects of treatment modalities for biliary atresia. However, it is clear that more needs to be done to best develop new treatment plans while applying the modalities we have (porto-enterostomy or liver transplantation or both) in a way that will afford the best survival and quality-of-life. This review article will discuss a number of points that are vital to improving care and illustrates the need to further scrutinize treatment decisions.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh：

Year:  2013        PMID： 23347466     DOI： 10.1111/petr.12040

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN： 1397-3142


  10 in total

1.  Design and validation of an early scoring system for predicting early outcomes of type III biliary atresia after Kasai's operation.

Authors:  Chen Zhen; Qiao Guoliang; Ma Lishuang; Zhang Zhen; Wang Chen; Zhang Jun; Liu Shuli; Guan Kaoping; Liu Chao; Yang Xuan; Li Long
Journal:  Pediatr Surg Int       Date:  2015-04-18       Impact factor: 1.827

2.  Onset ages of hepatopulmonary syndrome and pulmonary hypertension in patients with biliary atresia.

Authors:  Takehisa Ueno; Ryuta Saka; Yuichi Takama; Hiroaki Yamanaka; Yuko Tazuke; Kazuhiko Bessho; Hiroomi Okuyama
Journal:  Pediatr Surg Int       Date:  2017-09-04       Impact factor: 1.827

3.  Living Related Liver Transplantation for Biliary Atresia in the Last 5 years: Experience from the First Liver Transplant Program in India.

Authors:  Smita Malhotra; Anupam Sibal; Vidyut Bhatia; Akshay Kapoor; Sarath Gopalan; Swati Seth; Nameet Jerath; Manav Wadhawan; Subash Gupta
Journal:  Indian J Pediatr       Date:  2015-02-25       Impact factor: 1.967

4.  Prominin-1 Promotes Biliary Fibrosis Associated With Biliary Atresia.

Authors:  Jessica A Zagory; Michael Fenlon; William Dietz; Menghan Zhao; Marie V Nguyen; Pavin Trinh; Maeva Adoumie; Alex Park; Jiabo Xu; Elaa Mahdi; Alison Glazier; Nicolas Malkoff; Nirmala Mavila; Kasper S Wang
Journal:  Hepatology       Date:  2019-04-11       Impact factor: 17.425

5.  Laparoscopic revision of Kasai portoenterostomy after initial laparoscopic portoenterostomy in patients with biliary atresia: a limited but positive effect on native liver survival.

Authors:  Daiki Kato; Hiroo Uchida; Hizuru Amano; Akinari Hinoki; Chiyoe Shirota; Wataru Sumida; Kazuki Yokota; Satoshi Makita; Masamune Okamoto; Aitaro Takimoto; Akihiro Yasui; Shunya Takada; Yoichi Nakagawa
Journal:  Pediatr Surg Int       Date:  2022-09-14       Impact factor: 2.003

6.  Etiology, Clinical Presentations, and Short-Term Treatment Outcomes of Extrahepatic Obstructive Jaundice in South-Western Uganda.

Authors:  Charles Newton Odongo; Carlos Cabrera Dreque; David Mutiibwa; Felix Bongomin; Felix Oyania; Mvuyo Maqhawe Sikhondze; Moses Acan; Raymond Atwine; Fred Kirya; Martin Situma
Journal:  Clin Exp Gastroenterol       Date:  2022-06-11

7.  Long-Term Survival of Biliary Atresia without any Surgery: Lessons Learnt from Lamprey.

Authors:  V Raveenthiran
Journal:  J Neonatal Surg       Date:  2014-04-01

8.  Downregulation of Hes1 expression in experimental biliary atresia and its effects on bile duct structure.

Authors:  Rui-Zhong Zhang; Xin-Hao Zeng; Ze-Feng Lin; Yan-Lu Tong; Vincent Ch Lui; Paul Kh Tam; Jonathan R Lamb; Hui-Min Xia; Yan Chen
Journal:  World J Gastroenterol       Date:  2018-08-07       Impact factor: 5.742

9.  Programmed cell death protein-1 (PD-1) protects liver damage by suppressing IFN-γ expression in T cells in infants and neonatal mice.

Authors:  Xuangjie Guo; Yiping Xu; Wei Luo; Rongli Fang; Li Cai; Ping Wang; Yuxia Zhang; Zhe Wen; Yanhui Xu
Journal:  BMC Pediatr       Date:  2021-07-16       Impact factor: 2.125

10.  High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia.

Authors:  Erika K Fenner; Juri Boguniewicz; Rebecca M Tucker; Ronald J Sokol; Cara L Mack
Journal:  Pediatr Res       Date:  2014-04-11       Impact factor: 3.756
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.